All In Biotech

Drug Trial Radar · NCT05605535

Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer

A Phase 2, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial Comparing Chemoimmunotherapy (Paclitaxel-Carboplatin-Oregovomab) Versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) as Neoadjuvant Therapy in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma

Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

88

Planned (sponsor's estimate)

Start

Feb 7, 2023

Primary completion

May 15, 2027

Study completion Sep 15, 2027

Sponsor

Lead sponsor
CanariaBio Inc.Industry
Sponsor type
Industry
Collaborators
Raptim Research
First posted
Nov 4, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A clinical study to compare the efficacy and safety of five administrations of oregovomab versus placebo, infused in schedule dependent sequence with specific cycles of a standard six-cycle chemotherapy regimen (paclitaxel and carboplatin), for the treatment of patients with newly diagnosed advanced ovarian cancer who are planned to receive neoadjuvant treatment followed by interval debulking surgery (IDS) and adjuvant treatment.

Conditions

  • Ovarian Neoplasm Epithelial
  • Ovarian Cancer
  • Fallopian Tube Neoplasms
  • Peritoneal Carcinoma
  • Ovarian Serous Adenocarcinoma

Interventions

  • OregovomabBiological

    2 mg, dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes

  • PaclitaxelDrug

    175 mg/m\^2, every 3 weeks

  • CarboplatinDrug

    AUC 5 or 6 IV Day 1 x 6 cycles (every 21 days)

  • PlaceboBiological

    2 mg, dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS) Rate at 12 monthsTime frame: At 12 months

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Omega Hospitals

    Visakhapatnam, Andhra Pradesh, India

  • King George Hospital

    Visakhapatnam, Andhra Pradesh, India

  • Himalaya Cancer Hospital and Research Institute

    Vadodara, Gujarat, India

  • Kailash Cancer Hospital and Research Centre

    Vadodara, Gujarat, India

  • KLES Dr. Prabhakar Kore Hospital and Medical Research Centre

    Belagavi, Karnataka, India

  • Amrita Institute of Medical Sciences

    Kochi, Kerala, India

  • Regional Cancer Centre, Medical College

    Trivandrum, Kerala, India

  • JIPMER

    Puducherry, Puducherry, India

  • Sri Ram Cancer Hospital

    Jaipur, Rajasthan, India

  • Saveetha Medical College and Hospitals

    Chennai, Tamil Nadu, India

  • Sri Ramchandra Medical Centre

    Chennai, Tamil Nadu, India

  • MNJ Cancer Hospital

    Hyderabad, Telangana, India

  • King Georges Medical University

    Lucknow, Uttar Pradesh, India

  • Institute of Medical Sciences, BHU

    Varanasi, Uttar Pradesh, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.